Search Results
May 19, 2026, 08:36 ET TheWell Bioscience Launches Universal Xeno-Free Organoid Medium to Standardize Workflows and Reduce Costs
ScalingConsolidates multiple media systems into a single platform, helping reduce inventory burden and reagent waste.Advancing Standardization and NAMs AdoptionBy consolidating media components into a single defined system, RocketCell™ Essential-Core Medium supports efforts to standardize
More news about: TheWell Bioscience
May 07, 2026, 13:30 ET Capital Hilton Debuts New Art Installation and Vibrant Summer Lineup
Gallaudet University's Office of Arts, Culture, and Experience. Nam's work expresses his perspective through vibrant landscapes and scenic works. His style is free, passionate, and optimistic, creating a vivid "sound world"
More news about: Capital Hilton
May 06, 2026, 07:30 ET Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics
toward advanced human-relevant methods, including AI-powered models and human organ-on-chip systems, and has stated that New Approach Methodologies (NAMs) can improve predictivity, identify mechanisms of action, and support safer clinical development. The FDA has also announced plans to promote human
More news about: Galmed Pharmaceuticals Ltd.
May 04, 2026, 08:30 ET Accelerate Predictive Drug Discovery with Scalable 3D Human Functional Models, Upcoming Webinar Hosted by Xtalks
Attendees will understand why the synergy of assay-ready cells, scalable systems and automated data is the only path to regulatory-grade Non-Animal Models (NAMs). The featured speaker will discuss how optogenetic and electrical stimulation enable functionally mature 3D models for neuromuscular disease and potency
More news about: Xtalks
Apr 22, 2026, 10:06 ET Texas Biomed establishes new Tuberculosis Innovation and Technology Fund to improve research and treatments for world's deadliest infectious disease
These New Approach Methodologies (NAMs) at Texas Biomed accelerate discoveries and drug development by complementing required studies to ensure new medicines are safe for people.TB
More news about: Texas Biomedical Research Institute
Apr 20, 2026, 12:11 ET Texas Biomed advancing new approach methodologies (NAMs)
help establish biological standards for NAMs. A key focus is robustly studying how NAMs demonstrate safety and efficacy of a particular therapy, compared to well-established animal models. In this regard, investigators are incorporating animal cells into NAMs to help bridge the gap.However, at
More news about: Texas Biomedical Research Institute
Mar 23, 2026, 11:11 ET RIFM Celebrates 60 Years of Fragrance Safety with Special Series of Trainee Awards at SOT 2026
Ballroom A).These awards highlight RIFM's legacy of collaboration and its long-standing commitment to animal-free New Approach Methodologies (NAMs). By supporting these scientists, RIFM continues to build international trust in the safe use of fragrance materials through transparent, peer-reviewed
More news about: Research Institute for Fragrance Materials
Mar 19, 2026, 16:34 ET Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods
help realize the promise of NAMs and accelerate safer, faster drug development, Vanda calls on the FDA to:Withdraw the current draft and substantially revise it with stronger scientific grounding.Incorporate robust citations to validated NAMs, peer-reviewed studies, and specific,
More news about: Vanda Pharmaceuticals Inc.
Mar 18, 2026, 19:08 ET $25 Million Project Seeks to Coordinate Data Produced by Human-Based Testing Methods
advances of NAMs technologies.A defining feature of the NDHCC will be its FAIR, Unified Schema for Interoperability of Ontologies in NAMs (FUSION) framework, an approach to data standards that enables the hub to adapt its handling of multimodal data alongside the rapidly growing NAMs field. FUSION
More news about: NYU Langone Health System
Mar 09, 2026, 10:00 ET Generac's Jagdfeld Named to Manufacturers Association Board of Directors
power the U.S. economy. Approximately 85% of the NAM's members are small and medium-sized businesses. Executives on the NAM Board, which comprises leaders representing companies of all sizes in every industrial sector, are the driving force behind the NAM's efforts. The NAM is a one-stop
More news about: Generac Power Systems, Inc.
Mar 04, 2026, 08:36 ET TheWell Bioscience Launches RocketCell™ hMSC Xeno-Free Complete Growth Medium for Robust and Reproducible Expansion of Human Mesenchymal Stem Cells
reagents eliminates animal-derived variability, supports precision medicine, cell therapy, biomanufacturing, and advances New Approach Methodologies (NAMs).Media Contact:Kyra [email protected]
More news about: TheWell Bioscience
Mar 03, 2026, 08:00 ET Nickolas Asset Management Acquires Associated Plastics Corporation
large-scale manufacturing facility. The transaction expands NAM's footprint in Ohio to five manufacturing facilities and four distribution centers, representing more than one million square feet in the local region. This investment reinforces NAM's focus on asset- and infrastructure-heavy manufacturing.Associated
More news about: Nickolas Asset Management
Feb 24, 2026, 08:50 ET Draper and Partners Awarded ARPA-H Funding to Develop New In Silico Models of Human Physiology for Drug Development
(CATALYST) program, which will develop a new generation of in silico models of human physiology based on data from New Approach Methodologies (NAMs) to inform the drug development process.
More news about: Draper Laboratory
Feb 18, 2026, 08:50 ET Draper Achieves Sustained Recirculation of Immune Cells in a Microphysiological System (MPS)
highly controllable cell flow dynamics through the pump and microfluidic tissue models.The work demonstrates that New Approach Methodologies (NAMS), including MPS such as PREDICT96, can play a critical role in improving our holistic capacity to accurately and rapidly characterize biothreats. It
More news about: Draper Laboratory
Feb 10, 2026, 09:00 ET Nickolas Asset Management Acquires Resin Processing Facility from Material Difference Technologies
reprocessed plastic resins annually. The operation combines resin distribution with formulating, blending, and compounding capabilities, supporting NAM's manufacturing platform with tailored material solutions aligned to specific product, performance and customer requirements. The facility also provides
More news about: Nickolas Asset Management
Feb 09, 2026, 08:33 ET TheWell Bioscience Launches VitroPrime™ 3D Culture and Imaging Plate for Organoid and 3D Cell Culture Workflows
animal-derived variability, support scalable applications in precision medicine, cell therapy, and biomanufacturing, and advances New Approach Methodologies (NAMs) through more human-relevant in vitro models.Contact:Kyra Baricaua9738554955
More news about: TheWell Bioscience Inc.
Feb 02, 2026, 06:30 ET Bio-Techne Expands 3D Stem Cell and Organoid Culture Portfolio with a Fully Defined Synthetic Alternative
personalized medicine, reducing the reliance on animal-component derived matrices and supporting the broader utilization of new approach methodologies (NAMs). By avoiding the biological variability inherent in traditional ECMs, the hydrogel helps researchers standardize experimental conditions across studies
More news about: Bio-Techne Corporation
Jan 12, 2026, 09:30 ET Trailhead Biosystems Expands Financing to $40 Million
additional financing will enable Trailhead to further develop its portfolio of iPSC-derived human cell products, which support New Approach Methodologies (NAMs) for preclinical research and drug discovery. By providing physiologically relevant, reproducible human cell models, Trailhead's products help researchers
More news about: Trailhead Biosystems Inc
Jan 09, 2026, 12:40 ET M&G champions UK innovation in drug discovery by leading US$50 million funding round for biotech company bit.bio
for research, drug discovery, and toxicology, bit.bio is leading the global transition towards human-relevant New Approach Methodologies1 (NAMs), which use advanced cell-based and computational models instead of animal testing, and are reshaping how medicines are developed with greater predictiveness.M&G
More news about: bit.bio; M&G Investments
Jan 09, 2026, 12:31 ET M&G champions UK innovation in drug discovery by leading US$50 million funding round for biotech company bit.bio
for research, drug discovery, and toxicology, bit.bio is leading the global transition towards human-relevant New Approach Methodologies1 (NAMs), which use advanced cell-based and computational models instead of animal testing, and are reshaping how medicines are developed with greater predictiveness.M&G
More news about: bit.bio; M&G Investments
Dec 17, 2025, 03:30 ET Biologics X 3DCC Conference 2026: Merging Innovation, Drug Development, and Translation for the Next Era of Biopharma
converge 800+ global leaders and pioneers in biologics, biosimilars, cell-based technologies, advanced in-vitro models, New Approach Methodologies (NAMs), and translational research.Why Merge the Two Flagship Events:The convergence of Biologics and 3DCC unites two critical
More news about: Mumbai Biocluster
Dec 17, 2025, 03:26 ET Biologics X 3DCC Conference 2026: Merging Innovation, Drug Development, and Translation for the Next Era of Biopharma
converge 800+ global leaders and pioneers in biologics, biosimilars, cell-based technologies, advanced in-vitro models, New Approach Methodologies (NAMs), and translational research.Why Merge the Two Flagship Events:The convergence of Biologics and 3DCC unites two critical
More news about: Mumbai Biocluster
Dec 11, 2025, 06:30 ET Bio-Techne Partners with the Wyss Center Geneva to Advance Automated 3D Multiomics Technology and Accelerate Spatial Biology
barriers.Innovation has the potential to improve preclinical research by reducing reliance on animal testing through New Approach Methodologies (NAMs) such as organoids and predictive modeling, enabling new directions and scale in advanced biomedical studies.Partnership
More news about: Bio-Techne Corporation
Dec 11, 2025, 06:30 ET Bio-Techne Partners with the Wyss Center Geneva to Advance Automated 3D Multiomics Technology and Accelerate Spatial Biology
barriers.Innovation has the potential to improve preclinical research by reducing reliance on animal testing through New Approach Methodologies (NAMs) such as organoids and predictive modeling, enabling new directions and scale in advanced biomedical studies.Partnership
More news about: Bio-Techne Corporation
Dec 05, 2025, 14:23 ET Tessel Biosciences Awarded Up To $4.2M Through the ARPA-H CATALYST Program to Advance Drug Safety and ADMET Prediction
and all of our fellow consortium members."Tessel's contributions to the CATALYST program will accelerate the use of New Approach Methodologies (NAMs) for safer drug development through simulation. This work will also broaden the scope of Tessel's virtual tissue models, extending Tessel's platform
More news about: Tessel Biosciences